SCHEMBL210120

SCHEMBL210120

CC(c1cccnc1)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.61
CYP3A5 P20815 4/20 0.61
GPR119 Q8TDV5 2/20 0.54
PLA2G7 Q13093 1/20 0.54
MGLL Q99685 1/20 0.54
ABHD6 Q9BV23 1/20 0.54
GBA1 P04062 1/20 0.48
POLB P06746 1/20 0.48
KIT P10721 1/20 0.46
GRM5 P41594 1/20 0.45
GRM1 Q13255 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15093706 0.89 CYP3A4 (0.71) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL31071488 0.89 CYP3A4 (0.71) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL19668681 0.86 CYP3A4 (0.59) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL29363322 0.86 CYP3A4 (0.59) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL30476445 0.85 CYP3A4 (0.58) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL20818634 0.85 CYP3A4 (0.58) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL14035283 0.85 CYP3A4 (0.58) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL209672 0.85 GPR119 (0.49) CYP3A4CYP3A5GPR119POLBNPC1
SCHEMBL8115616 0.84 CYP2D6 (0.57) GPR119MGLLNPC1ALDH1A1MAPT
SCHEMBL3805489 0.84 CYP2D6 (0.57) GPR119MGLLNPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA CYP3A4 439/4885CYP3A5 883/4885GPR119 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.